German smart infusion therapy and pain management specialist B. Braun Medical Inc announced on Wednesday that it has received approval from the US Food and Drug Administration (FDA) for Piperacillin and Tazobactam, one of the most used injectable antibiotics in the United States, for use in the company's DUPLEX Drug Delivery System.

B. Braun will begin moving toward a full launch.

Piperacillin and Tazobactam in the DUPLEX Drug Delivery System is a ready-to-activate, two-compartment container that keeps pre-measured medication and diluent separate until the provider is ready to administer at the bedside by folding, squeezing and shaking to reconstitute. The company says that this system reduces overall process time by nearly four minutes per dose and shows substantial labour time savings compared to both the Baxter Mini-Bag Plus Container System and traditional compounding.

Piperacillin and Tazobactam in the DUPLEX Drug Delivery System will mark the second DUPLEX Drug launch in 2025 (in addition to Cefazolin 3g) and is one of several planned injectable drugs B. Braun will launch in the United States in the coming years.